• KOL
    • Prostate Cancer
    • Alan Wayne Partin
    • Alan Wayne Partin: Influence Statistics

      Alan Wayne Partin

      Alan Wayne Partin

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States | The James Buchanan Brady Urological Institute, Johns Hopkins ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Alan Wayne Partin:Expert Impact

      Concepts for whichAlan Wayne Partinhas direct influence:Prostate cancer,Radical prostatectomy,Specific antigen,Gleason score,Biochemical recurrence,Prostate specific,Pathological stage,Clinical stage.

      Alan Wayne Partin:KOL impact

      Concepts related to the work of other authors for whichfor which Alan Wayne Partin has influence:Prostate cancer,Specific antigen,Biochemical recurrence,Active surveillance,Gleason score,Prostatic neoplasms,Androgen receptor.

      KOL Resume for Alan Wayne Partin

      Year
      2021

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States

      Johns Hopkins Hospital, Baltimore, MD, USA

      2020

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA.

      Department of Urology, Brady Urological Institute, Johns Hopkins University, Baltimore, Maryland.

      2019

      Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA

      The Brady Urological Institute, The Johns Hopkins University , Baltimore , Maryland.

      2018

      James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

      2017

      Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

      James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD

      2016

      The James Buchanan Brady Urological Institute, Department of Urology, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Baltimore, MD 21287, USA

      Department of Urology, Northwestern University Feinberg School of Medicine (RSM, EMS), Chicago, Illinois

      James Buchanan Brady Urological Institute, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

      BALTIMORE, MARYLAND.

      2015

      James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, MD, USA

      Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland

      The Johns Hopkins Hosp, Baltimore, MD

      2014

      Johns Hopkins Hospital, Baltimore, Maryland

      Sungkyunkwan University Samsung Medical Center (BCJ), Seoul, South Korea

      Duke University Medical Center, Durham, North Carolina (SJF)

      2013

      All authors: Johns Hopkins University, Baltimore, MD.

      Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Alan Wayne Partin is among the top experts in the world.
      Concept World rank
      biopsies 1 cancer #1
      evidence bcr #1
      nj299 #1
      25 psa levels #1
      prostate cells blood #1
      scan ppv #1
      metastases mfs #1
      edalnetr #1
      tpsad cpsad #1
      early diagnosis pca #1
      cancer range #1
      threshold phid #1
      specific prostatic neoplasms #1
      complexed free #1
      sets gels #1
      ct2cnos #1
      prias protocols patients #1
      • rrp lrp #1
      radical prostatectomy hrpc #1
      blood prostate cancer #1
      magnetic resonance psa #1
      biopsy pathological stage #1
      nomograms psa #1
      surgical approach plnd #1
      721 #1
      genn models #1
      nuclear structure response #1
      fpsa percent #1
      patients jhh #1
      auc acpp #1
      serum proteomics pattern #1
      gg⩾2 #1
      sum 7 #1
      calculated psa ratio #1
      stage gleason score #1
      fold psa #1
      90 sensitivity #1
      cpsa positive threshold #1
      long noncoding pca #1
      delay months #1
      specificity tpsa #1
      chiaccherini #1
      documented metastasis #1
      search jhh #1
      aged disease #1
      survival rp #1
      libertino #1
      tpsa percent #1
      18209 #1
      tpsa 90 sensitivity #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Alan Wayne Partin

      KOL-Index: 24001

      OBJECTIVES: To determine the clinical significance of Gleason score 3+4 versus 4+3 on radical prostatectomy.

      METHODS: Of 2390 men who underwent radical prostatectomy by a single surgeon, 570 had Gleason score 7 tumors without lymph node metastasis, seminal vesicle invasion, or tertiary Gleason pattern 5. Patients were evaluated for biochemical recurrence (prostate-specific antigen progression) and distant metastases.

      RESULTS: Eighty percent of patients had Gleason score 3+4, 20% had 4+3. ...

      Known for Gleason Score | Radical Prostatectomy | 3 4 | Prognostic Significance | 7 Tumors
      KOL-Index: 19106

      CONTEXT: Biochemical disease recurrence after radical prostatectomy often prompts salvage radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to determine whether radiotherapy improves survival, and if so, the subgroup of men most likely to benefit.

      OBJECTIVES: To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups ...

      Known for Salvage Radiotherapy | Specific Survival | Prostate Cancer | Biochemical Recurrence | Hormonal Therapy
      KOL-Index: 18984

      PURPOSE: This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy.

      MATERIALS AND METHODS: Serum was collected before biopsy from 123 men with no prior biopsy or prostate cancer history. Specimens (cancer cases 51%, noncancer controls 49%) were selected equally from the 3 sites, and analyzed for prostate ...

      Known for Specific Antigen | Prostate Cancer Detection | Cancer Institute | Curve Biomarkers | Validation Study
      KOL-Index: 18544

      CONTEXT: The percentage of free prostate-specific antigen (PSA) in serum has been shown to enhance the specificity of PSA testing for prostate cancer detection, but earlier studies provided only preliminary cutoffs for clinical use.

      OBJECTIVE: To develop risk assessment guidelines and a cutoff value for defining abnormal percentage of free PSA in a population of men to whom the test would be applied.

      DESIGN: Prospective blinded study using the Tandem PSA and free PSA assays (Hybritech ...

      Known for Prostate Cancer | Percentage Free Psa | Benign Prostatic Disease | Specific Antigen | Unnecessary Biopsies
      KOL-Index: 17845

      PURPOSE: There have been only a few contradictory publications assessing whether Gleason score 4 + 3 = 7 has a worse prognosis than 3 + 4 = 7 on biopsy material in predicting pathological stage and biochemical recurrence. Older studies predated the use of the modified Gleason grading system established in 2005.

      MATERIALS AND METHODS: We retrospectively studied 1,791 cases of Gleason score 7 on prostatic biopsy to determine whether the breakdown of Gleason score 7 into 3 + 4 vs 4 + 3 has ...

      Known for Gleason Score | Radical Prostatectomy | Needle Biopsy | 7 Prostate | Primary Pattern
      KOL-Index: 17644

      PURPOSE: We addressed whether Gleason score 3 + 4 = 7 and 4 + 3 = 7 cancers on needle biopsy behave differently and whether this behavior is independent of the number of cores involved by cancer. If it is not an independent predictor of prognosis, one may report Gleason score 7 cancer with the number of positive cores without regard to whether the primary pattern was 3 or 4. This practice would remove a source of poor interobserver reproducibility when grading prostate cancer on needle ...

      Known for Needle Biopsy | 3 4 | Gleason Scores | Score 7 | Prostate Cancer
      KOL-Index: 17308

      We previously demonstrated the ability to detect metastatic prostate cancer using N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC), a low-molecular-weight radiotracer that targets the prostate-specific membrane antigen (PSMA). PSMA has been shown to be associated with higher Gleason grade and more aggressive disease. An imaging biomarker able to detect clinically significant high-grade primary prostate cancer reliably would address an unmet clinical ...

      Known for Dcfbc Pet | Prostate Cancer | Surface Biomarkers | Imaging 18f | Unmet Clinical
      KOL-Index: 16998

      WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The Gleason scoring system is a well-established predictor of pathological stage and oncological outcomes for men with prostate cancer. Modifications throughout the last few decades - most recently by the International Society of Urological Pathology (ISUP) in 2005 - have attempted to improve the correlation between biopsy and radical prostatectomy Gleason sum and better stratify patients to predict clinical outcomes. Based on ...

      Known for Gleason Grade | International Society | Positive Cores | Radical Prostatectomy Rp | Urological Pathology
      KOL-Index: 16926

      PURPOSE: Prostate specific antigen and free prostate specific antigen have limited specificity to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors. Specificity to detect clinically significant prostate cancer may be improved by [-2]pro-prostate specific antigen. We evaluated [-2]pro-prostate specific antigen, free prostate specific antigen and prostate specific antigen using the formula, ...

      Known for Prostate Specific | Multicenter Study | Biopsy Auc | Cancer Detection | Curve Biomarkers
      KOL-Index: 16880

      PURPOSE: Since 2010 pathologists at our institution have routinely been documenting the Gleason score at the margin and length of the positive surgical margin after prostatectomy. In this study we evaluate how the Gleason score and positive surgical margin length correlate with the grade and adverse pathological characteristics of the final specimen, and whether the positive surgical margin Gleason score affects the risk of early biochemical recurrence.

      MATERIALS AND METHODS: A total of ...

      Known for Gleason Score | Positive Surgical Margin | Radical Prostatectomy | Biochemical Recurrence | Aged Neoplasm
      KOL-Index: 16328

      PURPOSE: Percent free prostate specific antigen (PSA) is useful to select patients for prostate biopsy with total PSA 4 to 10 ng./ml. However, 20% of men with PSA between 2.6 and 4 ng./ml. harbor significant prostate cancer and percent free PSA has been suggested to aid in the decision to biopsy in this total PSA range as well. Concerns exist that the number of biopsies needed to detect 1 cancer in this range may be inappropriately high. In a prospective referral population we evaluated ...

      Known for Prostate Cancer | Percent Free | Specific Antigen | Psa Range | Gleason Score
      KOL-Index: 16259

      PURPOSE: Hypermethylation of the CpG island at the promoter region of the pi-class glutathione S-transferase gene (GSTP1) is the most common somatic genome abnormality in human prostate cancer. We evaluated circulating cell-free DNA GSTP1 CpG island hypermethylation as a prognostic biomarker in the serum of men with prostate cancer.

      EXPERIMENTAL DESIGN: Prostate cancer DNA GSTP1 CpG island hypermethylation was detected using a restriction endonuclease quantitative PCR technique. We ...

      Known for Radical Prostatectomy | Serum Dna | Cpg Island | Specific Antigen | Psa Recurrence
      KOL-Index: 16241

      PURPOSE: Determining serum total prostate specific antigen (PSA) has proved to be a valuable diagnostic aid for detecting prostatic carcinoma, although the lack of specificity has limited its usefulness. Studies indicate that the use of percent free PSA would improve specificity while maintaining sensitivity. Since complexed PSA represents the major proportion of measurable PSA in serum, we determined whether it represents a single test alternative to the use of percent free PSA for the ...

      Known for Complexed Prostate | Total Psa | Specific Antigen | Percent Free | Early Detection
      KOL-Index: 16208

      OBJECTIVES: To examine the relationship among needle biopsy primary grade, prostatectomy grade, and postprostatectomy biochemical recurrence among men with Gleason score 7 disease.

      METHODS: We identified 320 men with Gleason score 7 tumors on prostate biopsy treated with radical prostatectomy between 1991 and 2001 by a single surgeon. None of these patients had received neoadjuvant or adjuvant hormonal therapy or radiotherapy. The chi-square test and Kaplan-Meier method were used to ...

      Known for Gleason Pattern | Needle Biopsy | Radical Prostatectomy | Score 7 | Biochemical Recurrence

      Key People For Prostate Cancer

      Top KOLs in the world
      #1
      Ahmedin M Jemal
      united states breast cancer addis ababa
      #2
      Peter T Scardino
      prostate cancer active surveillance erectile function
      #3
      Rebecca L Siegel
      united states colorectal cancer incidence rates
      #4
      Johnathan I Jonathan
      prostate cancer gleason score needle biopsy
      #5
      Philip W Kantoff
      prostate cancer psma adc androgen deprivation therapy
      #6
      PATRICK CRAIG Walsh
      prostate cancer specific antigen pathological stage

      The Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, Maryland, 21287, United States | The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA | Johns Hopkins Hospital,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 KOL - Key Opinion Leaders, LLC.

    KOL does not provide medical advice, diagnosis or treatment.